Navigation Links
ViroPharma to Present at Several Upcoming Healthcare Conferences
Date:9/3/2009

EXTON, Pa., Sept. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting in four upcoming healthcare investment conferences during the month of September.

Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Rodman & Renshaw 11th Annual Global Healthcare Conference at 11:15 A.M. ET on Thursday, September 10, 2009. The conference is being held at the New York Palace Hotel.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Thomas Weisel Partners 2009 Global Healthcare Conference at 8:00 A.M. ET on Thursday, September 10, 2009. The conference is being held at the Four Seasons Hotel in Boston.

William Roberts, vice president, corporate communications will present at the BioCentury Newsmakers in the Biotech Industry Conference at 3:30 P.M. ET on Wednesday, September 16, 2009. The conference is being held at the Millennium Broadway Hotel in New York City.

Mr. Milano will also present at the ThinkEquity 6th Annual Growth Conference at 5:15 P.M. ET (2:15 P.M. PT) on Wednesday, September 16, 2009. The conference is being held at the St. Regis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of ant
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
2. ViroPharma to Present at Two June Healthcare Conferences
3. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
6. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
7. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
8. ViroPharma to Present at Three November Healthcare Conferences
9. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
10. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
11. ViroPharma to Present at Three October Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Four-dimensional (4-D) printing develops materials ... external stimuli such as changes in temperature. This ... effect in multiple industries.  In the near future, ... printing objects ranging from human organs to parts ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that clinical ... nimotuzumab, a humanized monoclonal antibody that targets,the epidermal ... American,Society of Clinical Oncology (ASCO) Annual Meeting being ...
... MONTVALE, N.J., June 3 Contemporary ... dedicated to enhancing the surgeon,s,practice, has announced ... tool:,SURGERYFINDIT.COM ( http://www.SURGERYFINDIT.COM )., As part ... surgeons with a wealth of peer-reviewed, practical ...
... 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ... device company, today announced the completion of U.S. ... track plug., "Our proprietary Bio-Seal product represents ... diagnose lung cancer," said Dr.,William Hunter, President and ...
Cached Biology Technology:NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 2NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 4SURGERYFINDIT.COM and Convera(R) Launch Vertical Search Site for Surgeons 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 3Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 4
(Date:8/20/2014)... years, Virginia Tech,s Wu Feng has built upon a ... "Computing in the Cloud" program, and synergistically complemented it ... from the Air Force on "big computing" for mini-drones ... National Institutes of Health on "big data" for the ... computing" aspects from each grant, he was able to ...
(Date:8/20/2014)... of honeybees grows to about 4,000 members, it triggers ... building of a special type of comb used for ... from the Department of Neurobiology and Behaviour at Cornell ... reproductive cycle of honeybee colonies. The results are published ... Nature . , Reproduction isn,t always a honeybee ...
(Date:8/20/2014)...  The second annual Biometrics UnPlugged Executive Summit, ... Florida on September 15, 2014, will ... and Strategy at Samsung, and Philippe de Raet, Vice ... this year,s event is Mobility at the Crossroads ... UnPlugged: Mobility at the Crossroads of Commerce & ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... created a synthetic protein that, when activated by ultraviolet light, ... arthritis and other serious medical disorders can be detected. ... imaging technology and may someday serve as a way to ... disease have been found. In a study published in the ...
... be changed by a restaurant,s choice of music and lighting, ... a new study., "When we did a makeover of a ... diners to eat 175 fewer calories and enjoy it more," ... and director of Cornell University,s Food and Brand Lab. ...
... Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market presents ... drug and treatment development for specific diseases. The global ... is projected to increase by 30% between 2010 and 2015, ... sector biobanks will experience the greatest increase with growth of ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
... gene gun system, 100-120 V, is used ... cells. This handheld device employs an adjustable ... other biomaterial-coated gold microcarriers from the inner ... into target cells. This system has a ...
...
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... screen, without Camera • ... mega pixel resolution. It is computer free for ... from large 5.6" TFT color liquid crystal display ... capture image for fluorescent gels, colorimetric gels, auto ...
Biology Products: